Abstract
Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.
Keywords: arrhythmias, Hypertension
Current Pharmaceutical Design
Title: Hypertension and Concurrent Arrhythmias
Volume: 9 Issue: 21
Author(s): Federico Lombardi and Paolo Terranova
Affiliation:
Keywords: arrhythmias, Hypertension
Abstract: Hypertension and cardiac arrhythmias commonly coexist in many patients. In this review, we will initially discuss arrhythmogenesis in hypertension, with particular emphasis on atrial and ventricular tachyarrhythmias and sudden cardiac death, whilst in the final part, we will focus our attention on the effects of anti-hypertensive therapies on supra-ventricular and ventricular arrhythmias and on sudden cardiac death prevention. Many patients with atrial fibrillation or frequent premature ventricular contractions have hypertension, and both need to be managed appropriately. Furthermore, hypertensive left ventricular hypertrophy could cause a wide variety of ventricular arrhythmias, which could end in sudden cardiac arrest. Most anti-hypertensive therapies, such as the β-blockers or ACE inhibitors, by slowing or interrupting the progression towards atrial and ventricular remodelling might exert some anti-arrhythmic effect, thus reducing the risk of sudden cardiac death in these patients.
Export Options
About this article
Cite this article as:
Lombardi Federico and Terranova Paolo, Hypertension and Concurrent Arrhythmias, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454496
DOI https://dx.doi.org/10.2174/1381612033454496 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Current Concepts in SLE Thrombocytopenia: From Pathophysiology to Therapeutic Interventions
Current Rheumatology Reviews The Treatment of Autoimmune Hepatitis
Current Clinical Pharmacology New Generation Calcium Channel Blockers in Hypertensive Treatment
Current Hypertension Reviews Common Genetic Variants of the Mitochondrial Trafficking System and Mitochondrial Uncoupling Proteins Affect the Development of Two Slowly Developing Demyelinating Disorders, Leukoaraiosis and Multiple Sclerosis
Current Medicinal Chemistry Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Supplementation of Creatine and Ribose Prevents Apoptosis and Right Ventricle Hypertrophy in Hypoxic Hearts
Current Pharmaceutical Design Editorial from Guest Editor [Hot Topic: Searching for Early Stages in Pathophysiology of Lung Disease: Cell Microenvironment (Guest Editor: Giuseppe Miserocchi)]
Current Respiratory Medicine Reviews A Neurotrophic Rationale for the Therapy of Neurodegenerative Disorders
Current Alzheimer Research subject Index To Volume 1
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Proteasomal Inhibition: A Novel Pathway for Prevention of Atherosclerosis and Restenosis
Vascular Disease Prevention (Discontinued) The Reno-Protective Effect of the Dual Blockade of the Renin Angiotensin System (RAS)
Current Pharmaceutical Design Exhaled Breath Biomarkers in Asthmatic Children
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)